These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 315269)
21. Immunologic and hematopoietic effects of CD40 stimulation after syngeneic bone marrow transplantation in mice. Funakoshi S; Taub DD; Anver MR; Raziuddin A; Asai O; Reddy V; Rager H; Fanslow WC; Longo DL; Murphy WJ J Clin Invest; 1997 Feb; 99(3):484-91. PubMed ID: 9022082 [TBL] [Abstract][Full Text] [Related]
22. Mechanisms of mouse T lymphocyte-induced suppression of the IgG2ab allotype and T lymphocyte tolerance to IgG2ab. Majlessi L; Bordenave G Arch Immunol Ther Exp (Warsz); 2001; 49(6):407-15. PubMed ID: 11814234 [TBL] [Abstract][Full Text] [Related]
23. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy. Giampietri A; Bonmassar A; Puccetti P; Circolo A; Goldin A; Bonmassar E Cancer Res; 1981 Feb; 41(2):681-7. PubMed ID: 7448813 [TBL] [Abstract][Full Text] [Related]
24. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316 [TBL] [Abstract][Full Text] [Related]
25. Tumor growth inhibitory and natural suppressor activities of murine bone marrow cells: a comparative study. Seledtsov VI; Taraban VY; Seledtsova GV; Samarin DM; Avdeev IV; Senyukov VV; Kozlov VA Cell Immunol; 1997 Nov; 182(1):12-9. PubMed ID: 9427805 [TBL] [Abstract][Full Text] [Related]
26. Effects of tumor bearing on the dynamics of host hemopoietic cells. Lala PK Cancer Treat Rep; 1976 Dec; 60(12):1781-9. PubMed ID: 1026335 [TBL] [Abstract][Full Text] [Related]
27. Influence of mammary tumor progression on phenotype and function of spleen and in situ lymphocytes in mice. Buessow SC; Paul RD; Lopez DM J Natl Cancer Inst; 1984 Jul; 73(1):249-55. PubMed ID: 6610791 [TBL] [Abstract][Full Text] [Related]
28. In vitro stimulation and inhibition of tumor cell growth mediated by different lymphoid cell populations. Norbury KC Cancer Res; 1977 May; 37(5):1408-15. PubMed ID: 66982 [TBL] [Abstract][Full Text] [Related]
29. Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression. Kurzawa H; Wysocka M; Aruga E; Chang AE; Trinchieri G; Lee WM Cancer Res; 1998 Feb; 58(3):491-9. PubMed ID: 9458095 [TBL] [Abstract][Full Text] [Related]
30. T cell-induced expression of membrane IgG by 70Z/3 B cells. Jacobs DH; Sneller MC; Misplon JA; Edison LJ; Kunimoto DY; Strober W J Immunol; 1986 Jul; 137(1):55-60. PubMed ID: 3086458 [TBL] [Abstract][Full Text] [Related]
31. Immune selection in murine tumors. Ph.d thesis. Svane IM; Engel AM APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251 [TBL] [Abstract][Full Text] [Related]
32. A syngeneic metastatic tumor model in mice: the natural immune response of the host and its manipulation. Treves AJ; Cohen IR; Feldman M Isr J Med Sci; 1976; 12(4-5):369-84. PubMed ID: 1084880 [TBL] [Abstract][Full Text] [Related]
33. Thymic humoral factor-gamma 2 (THF-gamma 2) immunotherapy reduces the metastatic load and restores immunocompetence in 3LL tumor-bearing mice receiving anticancer chemotherapy. Ophir R; Pecht M; Keisari Y; Rashid G; Lourie S; Meshorer A; Ben-Efraim S; Trainin N; Burstein Y Immunopharmacol Immunotoxicol; 1996 May; 18(2):209-36. PubMed ID: 8771368 [TBL] [Abstract][Full Text] [Related]
34. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. Wang J; Saffold S; Cao X; Krauss J; Chen W J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528 [TBL] [Abstract][Full Text] [Related]
35. The in vivo depletion of V beta 17a+ T cells results in the inhibition of reticulum cell sarcoma growth in SJL/J mice. Evidence for the use of anticlonotypic antibody therapy in the control of malignancy. Katz JD; Lebow LT; Bonavida B J Immunol; 1989 Aug; 143(4):1387-95. PubMed ID: 2663994 [TBL] [Abstract][Full Text] [Related]
36. Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells. Tsuchiya Y; Igarashi M; Suzuki R; Kumagai K J Immunol; 1988 Jul; 141(2):699-708. PubMed ID: 2968407 [TBL] [Abstract][Full Text] [Related]
37. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype. Lynch DH; Daynes RA; Hodes RJ J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117 [TBL] [Abstract][Full Text] [Related]
38. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. Levitsky HI; Montgomery J; Ahmadzadeh M; Staveley-O'Carroll K; Guarnieri F; Longo DL; Kwak LW J Immunol; 1996 May; 156(10):3858-65. PubMed ID: 8621924 [TBL] [Abstract][Full Text] [Related]
39. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells. Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687 [TBL] [Abstract][Full Text] [Related]
40. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]